• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Remodulin (treprostinil)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Remodulin (treprostinil)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Remodulin (treprostinil sodium) injection is a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class II-IV symptoms. Remodulin is intended to diminish the symptoms, such as shortness of breath, associated with physical activity in PAH patients.

    Remodulin is supplied in concentrations of 1.0 mg/mL, 2.5 mg/mL, 5.0 mg/mL and 10.0 mg/mL. The standard infusion rate is 1.25 ng/kg/min, but can be reduced in the event that the original dose cannot be tolerated.

    Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure.

    Clinical Results

    Two 12-week, multicenter, randomized, double-blind studies were conducted to compare Remodulin to placebo. A total of 470 subjects with NYHA Class II-IV pulmonary arterial hypertension (PAH) we enrolled in the studies. The baseline measures were 6-minute walking distance and level of shortness of breath during this physical test (Borg dyspnea score). The primary endpoint was change in 6-minute walking distance over the 12-week treatment period. There was a noteworthy change in 6-minute walking distance for those subjects treated with Remodulin, although the effects did not achieve conventional levels of statistical significance. There was a statistically significant change in subjects' Borg dyspnea scores with the Remodulin treatment. There were significant differences between Remodulin- and placebo-treated subjects in eight out of ten hemodynamic parameters that were evaluated, including cardiac index; mean pulmonary arterial pressure; pulmonary vascular resistance indexed; mean right atrial pressure; systemic vascular resistance indexed; mixed venous oxygen saturation. The two hemodynamic parameters that did not achieve statistical significance were mean systemic arterial pressure and heart rate.

    At the time of FDA approval, clinical studies of Remodulin were still ongoing for the PAH indication to explore further effects and potential benefits of the drug. In addition, a post-marketing, phase IV clinical trial is expected to commence.

    Side Effects

    In clinical trials, infusion site pain and infusion site reaction were the most frequently reported adverse events. Both of these effects were experienced by over 80% subjects receiving Remodulin therapy.

    The following adverse events were also reported in clinical trials:

    • Headache
    • Diarrhea
    • Nausea
    • Rash
    • Jaw pain
    • Vasodilatation
    • Dizziness
    • Edema
    • Pruritus (itching)
    • Hypotension

    Mechanism of Action

    The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. (From prescribing information)

    Additional Information

    For additional information about Remodulin, please visit the United Therapeutics web site at www.unither.com.

    Approval Date: 2002-05-01
    Company Name: United Therapeutics
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing